ArticleJournal for immunotherapy of cancer2026

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Huangming Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.